The Georgian Ministry of Health has announced a new addition to its state program for rare diseases, specifically for those living with cystic fibrosis. Under the new changes, the government will begin funding inhalation therapies, antibiotics, vitamin supplements and other medications necessary for managing the condition. Funding for hospital-based services for these patients will also increase.
This is the second major change to the rare disease program in 2025. In July, the ministry expanded drug and diagnostic coverage for multiple sclerosis patients living in the regions. The program’s total budget stands at 55 million GEL.
Health Minister Mikheil Sarjveladze personally presented the updates to families of patients during meetings held in Tbilisi and Kutaisi. He emphasized that the program adjustments were made in response to patients’ needs and through communication with their families. Sarjveladze also discussed planned further expansions, including the introduction of physiotherapy services and additional drug coverage.
The updated list of state-funded medicines includes antibiotics such as Tobramycin and Colomycin, fat-soluble vitamin complexes (A, D, E, K), hypertonic saline solutions, combination inhalation therapies, mucolytics like Acetylcysteine and hepatoprotective agents. The ministry noted that these treatments are expected to significantly improve patients’ quality of life, reduce complications and support better management of the disease. Distribution of the medicines will begin in stages in October and November.
